A 62-Year-Old Man Presents With Anemia & Fever

Poll

A 62-year-old man presents with anemia and fever. A renal mass is detected and a biopsy is performed. What is your diagnosis?

A 62-year-old man presents with anemia, fever, and a renal mass. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Sarcomatoid carcinoma
B. Clear cell carcinoma
C. Transitional cell carcinoma
D. Malakoplakia
Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content
Inflammation-induced epigenetic imprinting regulates intestinal stem cells

Inflammation-induced epigenetic imprinting regulates intestinal stem cells

American Society for Transplantation and Cellular Therapy
January 28th 2025
Article

Researchers from Bambino Gesù Children’s Hospital and Sapienza University in Rome, Italy examined the recovery and function of MAIT cells in pediatric and young adult patients following allo-HSCT.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The developers expect the product to be available for order in the United States in early February 2025.

FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD

Roman Fabbricatore
January 16th 2025
Article

The developers expect the product to be available for order in the United States in early February 2025.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes

CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes

ONCOLOGY Staff
January 1st 2025
Article

A Satellite Sessions event that took place at Fred Hutchinson Cancer Center and discussed treatments surrounding LCL and CLL.

New Developments in CAR T Treatments Webinar Series Summary

New Developments in CAR T Treatments Webinar Series Summary

American Society for Transplantation and Cellular Therapy
December 24th 2024
Article

The "New Developments in CAR T Treatments" webinar series brought together leading experts in the field of cancer immunotherapy to discuss the latest advancements and ongoing research in CAR T and natural killer cell therapies.